Pharma vet Valeria Fantin jumps to oncology team at Gilead; João Siffert out as Abeona looks for another CEO

Valeria Fantin

→ News broke on Twitter yesterday that Valeria Fantin has headed to Gilead to be their VP, oncology research, a field in which CEO Dan O’Day has placed particular emphasis with the $21 billion acquisition of Immunomedics. The well-traveled biopharma exec just completed a…

Click to view original post